Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, BGI Tech Ink Database Distribution Agreement

NEW YORK (GenomeWeb) – Qiagen and BGI Tech Solutions said today that they have signed a distribution and service agreement that allows BGI Tech to provide services and support around Qiagen's Human Gene Mutation Database (HGMD) to customers in China.

Qiagen acquired HGMD when it purchased Biobase in May this year. HGMD is a comprehensive database of human inherited disease mutations for use in genetics and genomic research. Its features include over 152,000 mutation reports including specifics on genome coordinates, sequence details, and links to the source material. It also includes over 5,300 summary reports that cover known inherited disease mutations for various genes.

"Collaborating with Qiagen can enrich our scientific strengths in the fields of human genetics and complex diseases, and enable us to provide better services for our global collaborators," Yingrui Li, BGI Tech's CEO, said in a statement.

Frank Schacherer, Biobase's CTO, added that "new and existing HGMD customers in Greater China will benefit from local support and from a distributor with deep subject-matter expertise."

Financial and other terms of the agreement were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.